October 4, 2023

VIA EMAIL AND EDGAR

U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention:         Jason Drory, Esq.
                         Division of Corporation Finance

Re:         IGC Pharma, Inc.
Registration Statement on Form S-3 (No. 333-274802)

Ladies and Gentlemen:

On behalf of IGC Pharma, Inc. (the “Company”), we enclose the Company’s request for acceleration of the above-referenced Registration Statement to 4:00 p.m., Eastern time, on Thursday, October 5, 2023, or as soon as possible thereafter.

Please advise the undersigned of the effectiveness of the Registration Statement.

Very truly yours,

/s/ Kenneth Schlesinger                                  

Kenneth Schlesinger

cc:          Mr. Ram Mukunda
Ms. Claudia Grimaldi

IGC Pharma, Inc.

10224 Falls Road

Potomac, MD 20854

October 4, 2023

U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention:         Jason Drory, Esq.
                         Division of Corporation Finance

Re:         IGC Pharma, Inc.
Registration Statement on Form S-3 (No. 333-274802)

Ladies and Gentlemen:

IGC Pharma, Inc. hereby requests that the effectiveness of the above-referenced Registration Statement be accelerated so that it will become effective at 4:00 p.m., Eastern time, on Thursday, October 5, 2023, or as soon as possible thereafter.

Very truly yours,
IGC PHARMA, INC.
By:	/s/ Ram Mukunda
	Ram Mukunda
	Chief Executive Officer and President